Medtronic Biz Pleads Guilty In Off-Label Marketing Case
Executive Summary
A Medtronic subsidiary has agreed to plead guilty for off-label marketing activities that occurred prior to Medtronic's acquisition. Overall, the firm says it has settled three investigations with a total pay-out of $50.9m. US FDA is underscoring the case as an example of the agency pursuing companies that "put profit over safety."